芩部通络方对耐多药肺结核患者免疫功能的作用研究

目的:研究芩部通络方对耐多药肺结核患者免疫功能的影响。方法:将符合纳入标准的78例患者随机分为对照组36例和治疗组42例。对照组给予常规西医化疗方案,参照《耐药结核病化学治疗指南(2009)-中国防痨协会》制定;治疗组在对照组治疗基础上,予以芩部通络方治疗。治疗18个月后观察患者肺部病灶和免疫功能的变化。结果:治疗12月后,治疗组肺部病灶改善情况明显优于对照组(P0.05),CD3、CD4及CD4/CD8值均大于对照组(P0.05或P0.01),治疗6月和18月后两组差异无统计学意义(P0.05)。结论:芩部通络方治疗耐多药肺结核疗效确切,其机制可能与增强机体免疫功能有关。

Clinical Study on Scutellaria-stemonae Network Vessels Freeing Formula for MDR-PTB in Immune Function

Objective：To study the clinical efficacy of Scutellaria-stemonae network vessels freeing formula on MDR-PTB in immune function. Methods： The 78 cases patient meeting inclusion criteria were randomly divided into control and treatment groups, 36 and 42 cases respectively in each. Patients were given routine chemotherapy treatment in control group with reference to the treatment of drug-resustant TB chemistry guide （2009）, China association of the chemotherapy, and chemotherapy treat- ment as well as Scutellaria- stemonae network vessels freeing formula in treatment group. Pulmonary lesions and changes in im- mune function were observed in 18 months. Results： After 12 months of treatment, the improvement of enhancement of the chest imaging in treatment group was better than that of the control group（P〈0.05）, and the value of CD3,CD4 and CD4/CD8 were greater than that of the control group（P〈0.05 or P〈0.01）, but the difference of the above data after treatment in 6 months and 6 months showed no statistical significance between the two groups （P〉0.05）. Conclusion： Scutellariastemonae network vessels freeing formula can provide accurate effect for MDR-PTB, the mechanism of which may be related to improving the body immunity.